Entera Bio (ENTX) Change in Receivables (2021 - 2024)

Entera Bio's (ENTX) quarterly Change in Receivables came in at -$7000.0 in Q4 2024, down 109.21% on a QoQ basis from $76000.0 in Q3 2024.

Entera Bio (ENTX) Change in Receivables (2021 - 2024) Analysis & Trends

Entera Bio (ENTX) has 4 years of Change in Receivables data on file, last reported at -$7000.0 in Q4 2024.

Quarterly Change in Receivables changed N/A year-over-year to -$7000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $69000.0 (down 45.24% YoY) and the FY2025 annual result came in at -$126000.0, down 200.0% from the prior year.
Change in Receivables eased to -$7000.0 in Q4 2024, from $76000.0 in the prior quarter.
In the past five years, Change in Receivables ranged from a high of $136000.0 in Q3 2021 to a low of -$240000.0 in Q1 2021.
A 4-year average of -$9923.1 and a median of $13000.0 in 2022 frame the typical range for Change in Receivables.
Annual changes were most pronounced in 2023 — Change in Receivables plunged 903.7% — and 2024, when it jumped 362.07%.
Tracing ENTX's Change in Receivables over 4 years: stood at -$69000.0 in 2021, then soared by 118.84% to $13000.0 in 2022, then slumped by 323.08% to -$29000.0 in 2023, then jumped by 75.86% to -$7000.0 in 2024.
The last three Change in Receivables figures came in at -$7000.0 (Q4 2024), $76000.0 (Q3 2024), and $57000.0 (Q2 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	140.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	838.50 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-53.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	117.58 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	31.60 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	94.29 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	37.16 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Entera Bio	161.44 Mn	150.13 Mn	-	-

Download Data